ANP.AX - Antisense Therapeutics Limited
| Previous close | 0.0670 |
| Open | 0.0670 |
| Bid | 0.0650 x 0 |
| Ask | 0.0680 x 0 |
| Day's range | 0.0640 - 0.0680 |
| 52-week range | 0.0290 - 0.1450 |
| Volume | 1,568,400 |
| Avg. volume | 2,315,067 |
| Market cap | 32.26M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0080 |
| Earnings date | 01 Mar 2016 - 05 Mar 2016 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Antisense Therapeutics (ASX:ANP) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Business Wire
Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints
Antisense Therapeutics ("ANP" or the "Company" ASX:ANP | US OTC:ATHJY) is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.
- Simply Wall St.
The Antisense Therapeutics (ASX:ANP) Share Price Is Down 43% So Some Shareholders Are Getting Worried
Antisense Therapeutics Limited (ASX:ANP) shareholders will doubtless be very grateful to see the share price up 44% in...
- Simply Wall St.
Should You Be Pleased About The CEO Pay At Antisense Therapeutics Limited's (ASX:ANP)
Mark Diamond became the CEO of Antisense Therapeutics Limited (ASX:ANP) in 2001. First, this article will compare CEO...
- Simply Wall St.
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. By way of example, Antisense...
- Simply Wall St.
Does The Antisense Therapeutics Limited (ASX:ANP) Share Price Fall With The Market?
Anyone researching Antisense Therapeutics Limited (ASX:ANP) might want to consider the historical volatility of the...
- Simply Wall St.
Should You Worry About Antisense Therapeutics Limited's (ASX:ANP) CEO Salary Level?
Mark Diamond became the CEO of Antisense Therapeutics Limited (ASX:ANP) in 2001. This report will, first, examine the...
